Recent research published in The Lancet evaluating the impact of GLP-1 drugs on Parkinson's disease has revealed disappointing findings. A trial involving exenatide, a drug related to Ozempic, demonstrated no improvement or slowing of the disease after 96 weeks in patients. Experts, including Dr. Thomas Foltynie and Dr. Michael S. Okun, expressed their disappointment, emphasizing the rigorous nature of the study and the lack of expected positive outcomes. This news is particularly disheartening for the half million diagnosed with Parkinson's, as it offers no new hope for slowing the disease's progression or alleviating symptoms.
A rigorous study randomly assigned Parkinson's patients to take exenatide, a relative of Ozempic, showing no benefit or slowing of degenerative disease after 96 weeks.
Researchers expected positive results from GLP-1 drugs for treating Parkinson's, but the study published in The Lancet yielded disappointing results with no effect on symptoms or brain scans.
Dr. Thomas Foltynie, who led the trial, expressed disappointment, stating, "We were expecting we would come through and we would get a positive result."
Dr. Michael S. Okun referred to the study as a "sobering moment," noting, "This is a really well done study and it came up empty-handed."
Collection
[
|
...
]